Spectrum Pharma (NASDAQ:SPPI): Cancer Biotech Takeover Target

Tuesday, 30 June 2009 00:00

Spectrum Pharmaceuticals (Nasdaq: SPPI) has two upcoming dates with regulators in the coming days and months.

July 2 Zevalin

October 8 Fusilev

Bayer Schering (Bayer) markets Zevalin in Europe and abroad - all countries ex. US. Bayer received approval for Zevalin as a first-line consolidation therapy on April 28, 2008. For details, please refer to my recent article here and here.

Here are 17 good reasons why Bayer might seriously consider acquiring Spectrum Pharmaceuticals (Nasdaq: SPPI) at some point in the future. Listed below are 17 ongoing clinical trials for Zevalin. Each trial is sorted by its corresponding completion date. Data source: FDA.

2009

August

Phase 2

Fludarabine Plus Zevalin . . .

September

Phase 2

Response Study of Zevalin in Patients with DLBCL after 6 cycles of CHOP

December

Phase 3

Study Comparing Zevalin Regimen with NO further treatment in DLBCL

Patients who are in Complete Remission after CHOP-R

2010

January	Phase 2	Zevalin in Combination with Z-CHOP in Treating Patients with Stage 2-4 DLBCL
July	Phase 2	Zevalin + Rituxan Maintenance Sponsor: University of Wisconsin
August	Phase 2	Autologous Stem Cell Transplant with Zevalin + Busulfan
December	Phase 2	Chemo followed by Zevalin for Relapsed Mantle Cell Lymphoma Sponsor: Dana-Faber Cancer Institute

2011

January

Phase 2

Safety of Zevalin,

Sponsor: Bayer Schering

2012

January	Phase 2	Zevalin Twice in Aggressive NHL
January	Phase 2	Safety Study to Evaluate Induction & Consolidation Treatment in Mantle Cell Lymphoma
June	Phase 3	Zevalin-BEAM for aggressive lymphoma Sponsor: Sheba Medical Center
December	Phase 1 / 2	Zevalin with Non Myeloablative Allogeneic Stem Cell Transplant in NHL

2013

April

Phase 2

Consolidation Treatment with Zevalin after R-CHOP Induction in

High Risk Patients According to FLIPI with fNHL

2014

June

Phase 2

Zevalin-BEAM with Autologous Stem Cell

August

Phase 2

Zevalin & Simultaneous Application of BEAM High Dose Chemo

October

Phase 2

Zevalin First-Line fNHL

Sponsor: Charite University, Berlin, Germany

2016

December

Phase 2

R-CHOP in fNHL Patients NOT Previously Treated. Consolidation with Zevalin

versus Maintenance with Rituxan

CONCLUSION

Though it is NOT possible to conclude that Bayer will acquire SPPI with any certainty, however, it does seem plausible.

Contributed by This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Disclosure: Long SPPI

BiomedReports is not paid or compensated to report news and developments about publicly traded companies. Full disclosure can be read at the bottom of / About Us / Section

Add this page to your favorite Social Bookmarking websites